Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Inozyme Pharma Inc has a consensus price target of $14.08 based on the ratings of 12 analysts. The high is $30 issued by Piper Sandler on January 13, 2025. The low is $4 issued by Wells Fargo on May 16, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Jefferies, and Needham on May 16, 2025, respectively. With an average price target of $6.67 between Wells Fargo, Jefferies, and Needham, there's an implied 68.99% upside for Inozyme Pharma Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/16/2025 | Buy Now | 1.39% | Wells Fargo | Tiago Fauth42% | → $4 | Downgrade | Overweight → Equal-Weight | Get Alert |
05/16/2025 | Buy Now | 1.39% | Jefferies | Ryan Deschner68% | $15 → $4 | Downgrade | Buy → Hold | Get Alert |
05/16/2025 | Buy Now | 204.18% | Needham | Joseph Stringer50% | $12 → $12 | Downgrade | Buy → Hold | Get Alert |
05/14/2025 | Buy Now | 204.18% | Needham | Joseph Stringer50% | $15 → $12 | Maintains | Buy | Get Alert |
04/10/2025 | Buy Now | 305.58% | HC Wainwright & Co. | Edward White45% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
04/08/2025 | Buy Now | 280.23% | Needham | Joseph Stringer50% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
03/12/2025 | Buy Now | 204.18% | Raymond James | Ryan Deschner68% | $24 → $12 | Maintains | Outperform | Get Alert |
03/11/2025 | Buy Now | 483.02% | Piper Sandler | Allison Bratzel62% | $30 → $23 | Maintains | Overweight | Get Alert |
03/11/2025 | Buy Now | 280.23% | Needham | Joseph Stringer50% | $23 → $15 | Maintains | Buy | Get Alert |
03/11/2025 | Buy Now | 305.58% | HC Wainwright & Co. | Edward White45% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
01/13/2025 | Buy Now | 660.46% | Piper Sandler | Christopher Raymond53% | $43 → $30 | Maintains | Overweight | Get Alert |
01/13/2025 | Buy Now | 178.83% | Wells Fargo | Tiago Fauth42% | $14 → $11 | Maintains | Overweight | Get Alert |
01/13/2025 | Buy Now | 305.58% | HC Wainwright & Co. | Edward White45% | $14 → $16 | Maintains | Buy | Get Alert |
01/10/2025 | Buy Now | 305.58% | HC Wainwright & Co. | Edward White45% | $14 → $16 | Maintains | Buy | Get Alert |
11/06/2024 | Buy Now | 254.88% | HC Wainwright & Co. | Edward White45% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
11/06/2024 | Buy Now | 483.02% | Needham | Joseph Stringer50% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
10/25/2024 | Buy Now | 483.02% | Needham | Joseph Stringer50% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
10/25/2024 | Buy Now | 254.88% | HC Wainwright & Co. | Edward White45% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
09/30/2024 | Buy Now | 280.23% | Wedbush | David Nierengarten57% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
09/12/2024 | Buy Now | 305.58% | Stifel | Dae Gon Ha46% | → $16 | Initiates | → Buy | Get Alert |
08/13/2024 | Buy Now | 330.93% | Jefferies | Maury Raycroft31% | $16 → $17 | Assumes | Buy → Buy | Get Alert |
08/08/2024 | Buy Now | 254.88% | HC Wainwright & Co. | Edward White45% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
08/06/2024 | Buy Now | 483.02% | Needham | Joseph Stringer50% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
07/26/2024 | Buy Now | 280.23% | Wedbush | David Nierengarten57% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
07/02/2024 | Buy Now | 254.88% | HC Wainwright & Co. | Edward White45% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
05/30/2024 | Buy Now | 254.88% | Wells Fargo | Tiago Fauth42% | → $14 | Initiates | → Overweight | Get Alert |
05/08/2024 | Buy Now | 483.02% | Needham | Joseph Stringer50% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
04/10/2024 | Buy Now | 483.02% | Needham | Joseph Stringer50% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
04/09/2024 | Buy Now | 483.02% | Needham | Joseph Stringer50% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
04/09/2024 | Buy Now | 254.88% | B of A Securities | Tazeen Ahmad53% | $16 → $14 | Maintains | Buy | Get Alert |
03/13/2024 | Buy Now | 305.58% | HC Wainwright & Co. | Edward White45% | $16 → $16 | Maintains | Buy | Get Alert |
03/12/2024 | Buy Now | 483.02% | Needham | Joseph Stringer50% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
01/30/2024 | Buy Now | 280.23% | Wedbush | David Nierengarten57% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
11/08/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | Buy → Buy | Get Alert |
09/27/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | Buy → Buy | Get Alert |
09/08/2023 | Buy Now | 280.23% | Wedbush | David Nierengarten57% | → $15 | Maintains | Outperform | Get Alert |
08/09/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | Buy → Buy | Get Alert |
08/08/2023 | Buy Now | 305.58% | HC Wainwright & Co. | Edward White45% | → $16 | Reiterates | Buy → Buy | Get Alert |
08/04/2023 | Buy Now | 305.58% | HC Wainwright & Co. | Edward White45% | $19 → $16 | Maintains | Buy | Get Alert |
07/27/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | Buy → Buy | Get Alert |
05/10/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | → Buy | Get Alert |
04/19/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | → Buy | Get Alert |
03/23/2023 | Buy Now | 52.09% | Jefferies | Suji Jeong26% | $4.5 → $6 | Upgrade | Hold → Buy | Get Alert |
03/23/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | → Buy | Get Alert |
02/17/2023 | Buy Now | 406.97% | HC Wainwright & Co. | Edward White45% | → $20 | Reiterates | → Buy | Get Alert |
02/17/2023 | Buy Now | 483.02% | Needham | Joseph Stringer50% | → $23 | Reiterates | → Buy | Get Alert |
05/26/2022 | Buy Now | 26.74% | Jefferies | Suji Jeong26% | → $5 | Initiates | → Hold | Get Alert |
The latest price target for Inozyme Pharma (NASDAQ:INZY) was reported by Wells Fargo on May 16, 2025. The analyst firm set a price target for $4.00 expecting INZY to rise to within 12 months (a possible 1.39% upside). 26 analyst firms have reported ratings in the last year.
The latest analyst rating for Inozyme Pharma (NASDAQ:INZY) was provided by Wells Fargo, and Inozyme Pharma downgraded their equal-weight rating.
The last upgrade for Inozyme Pharma Inc happened on March 23, 2023 when Jefferies raised their price target to $6. Jefferies previously had a hold for Inozyme Pharma Inc.
The last downgrade for Inozyme Pharma Inc happened on May 16, 2025 when Wells Fargo changed their price target from N/A to $4 for Inozyme Pharma Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a downgraded with a price target of $0.00 to $4.00. The current price Inozyme Pharma (INZY) is trading at is $3.95, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.